These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15971352)

  • 1. PIs associated with increased risk of cardiovascular disease.
    Carter M
    IAPAC Mon; 2005 Feb; 11(2):37. PubMed ID: 15971352
    [No Abstract]   [Full Text] [Related]  

  • 2. [Possible cardiovascular complications. What leads to "switching"].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():82. PubMed ID: 12043091
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
    Moyle GJ
    AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.
    Rhew DC; Bernal M; Aguilar D; Iloeje U; Goetz MB
    Clin Infect Dis; 2003 Oct; 37(7):959-72. PubMed ID: 13130409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.
    AIDS Alert; 2006 Feb; 21(2):17-8. PubMed ID: 16562335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.
    Cohen CJ
    AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia.
    Kannel WB; Giordano M
    Am J Cardiol; 2004 Oct; 94(7):901-6. PubMed ID: 15464673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system.
    Reyskens KM; Essop MF
    Biochim Biophys Acta; 2014 Feb; 1842(2):256-68. PubMed ID: 24275553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual dysfunction with PIs.
    AIDS Patient Care STDS; 1999 Jun; 13(6):376. PubMed ID: 10842862
    [No Abstract]   [Full Text] [Related]  

  • 12. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic side effects of antiretroviral therapy].
    van der Valk M; Reiss P
    Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drugs and the risk of myocardial infarction.
    Zangerle R; Sarcletti M
    N Engl J Med; 2007 Aug; 357(7):715-6; author reply 716-7. PubMed ID: 17703532
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on cardiovascular complications in HIV infection.
    Currier JS
    Top HIV Med; 2009; 17(3):98-103. PubMed ID: 19675367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV.
    Moyle G
    Int J STD AIDS; 2005 Oct; 16 Suppl 1():14-20; discussion 20-2, 41-3. PubMed ID: 16238827
    [No Abstract]   [Full Text] [Related]  

  • 20. [The HIV protease inhibitor-induced insulin resistance syndrome].
    Schütt M; Meier M; Klein HH
    Med Klin (Munich); 2003 Apr; 98(5):271-6. PubMed ID: 12721672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.